Kantar Health Blog

  • User Not Found
    The development of treatment pathways is very relevant to clinical development and understanding the competitive landscape. Fundamental changes in treatment approaches, along with payment reform, are required to meaningfully slow healthcare cost growth. Payers face various drug coverage mandates at the state and federal levels, making utilization and cost control challenging.
    Continue Reading > | Go comment! | Share
  • The Belle of the Ball: PD-1 as a Hot New Target

    by User Not Found | Jun 5, 2012
    User Not Found
    These studies demonstrate the potential of targeting the PD-1/PD-L1 checkpoint as a therapeutic strategy. These molecules appear to be very well tolerated and have efficacy in many advanced tumor types. Many questions remain unanswered about this novel approach to targeting cancer including: is efficacy limited to tumors that express PD-L1? ASCO 2012
    Continue Reading > | Go comment! | Share
  • User Not Found
    It is likely that dabrafenib and trametinib will receive regulatory approval though GSK has yet to file. With a somewhat better safety profile than Zelboraf, it will be a worthy competitor in the melanoma market and provide a treatment alternative for patients with BRAF mutations. Preliminary data from the combination of dabrafenib and trametinib looks very impressive in terms of safety and efficacy and may ultimately prove superior. ASCO 2012
    Continue Reading > | Go comment! | Share
  • User Not Found
    With the positive data, cabozantinib will clearly represent a new treatment option for MTC patients when it gets approved. But how will it be used by physicians? Will it compete with Caprelsa which earned its MTC regulatory approval in the U.S. in 2011 based on the results of ZETA Phase III trial, or will it be used after patients progress on Caprelsa? ASCO 2012
    Continue Reading > | Go comment! | Share
  • User Not Found
    Despite the high utilization of Tarceva in the United States, it currently is not FDA approved in the first-line setting. This lack of approval created an opportunity for afatinib to enter this market without directly challenging the market leader in a head-to-head clinical trial. The LUX-LUNG-3 results might push Roche into finally filing for Tarceva approval in the US. ASCO 2012
    Continue Reading > | Go comment! | Share
Page